Sabiia Seb
PortuguêsEspañolEnglish
Embrapa
        Busca avançada

Botão Atualizar


Botão Atualizar

Ordenar por: 

RelevânciaAutorTítuloAnoImprime registros no formato resumido
Registros recuperados: 3
Primeira ... 1 ... Última
Imagem não selecionada

Imprime registro no formato completo
Development and validation of highly selective method for the determination of imatinib mesylate and dexketoprofen trometamol combination in three different media BJPS
Coban,Ozlem; Degim,Zelihagul.
Imatinib mesylate is a small molecule used in cancer therapy as a thyrosine kinase inhibitor. Dexketoprofen trometamol is a non-steroidal anti-inflammatory drug that has seen use in cancer therapy in combination with an anticancer drug to minimize tumor size and to reduce pain in patients. In the present study, imatinib mesylate and dexketoprofen trometamol were selected as potential model drugs to be used in combination. A new, simple and selective Ultra Performance Liquid Chromatography method was developed and validated to determine the drug substances in distilled water, in a pH 7.4 phosphate buffer and in Dulbecco’s Modified Eagle Medium. The proposed method was developed using a BEH C-18 column with isocratic elution. A mixture of...
Tipo: Info:eu-repo/semantics/article Palavras-chave: Imatinib mesylate; Dexketoprofen trometamol; Ultra Performance Liquid Chromatography; Dulbecco’s Modified Eagle Medium.
Ano: 2020 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502020000100575
Imagem não selecionada

Imprime registro no formato completo
In vitro inhibitory effects of imatinib mesylate on stromal cells and hematopoietic progenitors from bone marrow BJMBR
Soares,P.B.; Jeremias,T.S.; Alvarez-Silva,M.; Licínio,M.A.; Santos-Silva,M.C.; Vituri,C.L..
Imatinib mesylate (IM) is used to treat chronic myeloid leukemia (CML) because it selectively inhibits tyrosine kinase, which is a hallmark of CML oncogenesis. Recent studies have shown that IM inhibits the growth of several non-malignant hematopoietic and fibroblast cells from bone marrow (BM). The aim of the present study was to evaluate the effects of IM on stromal and hematopoietic progenitor cells, specifically in the colony-forming units of granulocyte/macrophage (CFU-GM), using BM cultures from 108 1.5- to 2-month-old healthy Swiss mice. The results showed that low concentrations of IM (1.25 µM) reduced the growth of CFU-GM in clonogenic assays. In culture assays with stromal cells, fibroblast proliferation and α-SMA expression by...
Tipo: Info:eu-repo/semantics/article Palavras-chave: Bone marrow stromal cell; Hematopoietic progenitors; Imatinib mesylate; Myelosuppression.
Ano: 2013 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2013000100039
Imagem não selecionada

Imprime registro no formato completo
Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia BJMBR
Oliveira,G.A.P.; Costa,E.S.; Freitas,M.S.; Dutra,F.F.; Maia,S.F.; Guerra,M.C.; Tabernero,M.D.; Borojevic,R.; Otazu,I.B.; Silva,J.L..
Chronic myeloid leukemia (CML) is rare in the pediatric population, accounting for 2-3% of childhood leukemia cases, with an annual incidence of one case per million children. The low toxicity profile of imatinib mesylate has led to its approval as a front-line therapy in children for whom interferon treatment has failed or who have relapsed after allogeneic transplantation. We describe the positive responses of 2 children (case 1 - from a 7-year-old male since May 2005; case 2 - from a 5-year-old female since June 2006) with Philadelphia-positive chromosome CML treated with imatinib (300 mg/day, orally) for up to 28 months, as evaluated by morphological, cytogenetic, and molecular approaches. Our patients are alive, are in the chronic phase, and are in...
Tipo: Info:eu-repo/semantics/report Palavras-chave: Chronic myeloid leukemia; Imatinib mesylate; Minimal residual disease; Children.
Ano: 2010 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2010000600009
Registros recuperados: 3
Primeira ... 1 ... Última
 

Empresa Brasileira de Pesquisa Agropecuária - Embrapa
Todos os direitos reservados, conforme Lei n° 9.610
Política de Privacidade
Área restrita

Embrapa
Parque Estação Biológica - PqEB s/n°
Brasília, DF - Brasil - CEP 70770-901
Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco

Valid HTML 4.01 Transitional